Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients

Peking University People's Hospital20 enrolled

Overview

Previous study showed circulating tumor DNA levels reflect the total systemic tumor burden. Circulating tumor DNA levels should decrease after complete surgery and could be increase as tumor recurrence. Few study investigated the half time of circulating tumor DNA in lung cancer patients that no criterion has been established of how to use it for surveillance.

For lung cancer patients who received surgery, multiple time of plasma will be collected before or after surgery. A series of mutations will be detected in plasma before surgery based on next generation sequencing. The positive mutation will be traced after surgery and in follow up.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma Non-small-cell Lung Cancer Lung Neoplasms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Suspected lung cancer before surgery * No malignant tumor history within the past 5 years * The pulmonary nodule is not pure ground glass opacity * Patients must have given written informed consent Exclusion Criteria: * Multiple primary lung cancer * R1,R2 resection * Histology confirmed not non-small cell lung cancer * Unqualified blood samples

Locations (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Half-life of circulating tumor DNA after surgery

Time frame: 3 months

Secondary Outcomes

The variation of circulating tumor DNA level before and after surgery

Time frame: 3 months

Correlation of circulating tumor DNA level after surgery with tumor recurrence

Time frame: 3 years

Correlation of circulating tumor DNA level after surgery with clinical features

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.